|
WO2013021355A1
|
|
Functionalized calixarene derivatives for cell transfection
|
|
WO2012097869A1
|
|
Derivatives of nicotinic acid n-oxide, their preparation and their use as inhibitors of enzyme 3-hydroxyanthranilate-3,4-dioxygenase
|
|
EP2226395A1
|
|
Method and Kit for the detection of allergens
|
|
WO2010076764A1
|
|
Irreversible egfr inhibitor compounds with antiproliferative activity
|
|
EP2236208A1
|
|
Reactor device for chemical and isotopic analyses
|
|
EP2313114A2
|
|
A drug powder for inhalation administration and a process thereof
|
|
WO2008087157A2
|
|
Device for the treatment of tinnitus
|
|
EP2115011A1
|
|
Cytocompatible stable gel compositions as supports for cell growth
|
|
WO2009052869A1
|
|
Compositions in powder form made of soft agglomerates of a micronized drug and of a two-components excipient, and process for their preparation
|
|
EP2031387A1
|
|
Reactor device for isotopic analyses
|
|
WO2007132332A2
|
|
Surgical instrument for corneal transplants
|
|
US2010074926A1
|
|
Modules, new assemblage kits and new assembles for the controlled release of substances
|
|
EP1948793A2
|
|
Method for conversion of uric acid to allantoin and related enzymes
|
|
WO2005092301A1
|
|
Insulin highly respirable microparticles
|
|
WO03043601A2
|
|
Modular systems for the controlled release of a substance with space and time control
|
|
EP1441699A2
|
|
Powder for nasal administration of drugs
|
|
ITMI912948D0
|
|
Process for the regionally and stereoselective synthesis of p-hydroxymandelic acids and analogues
|
|
IT8942508D0
|
|
Compounds of rare soils with functioning calixarene and their use as luminescent probes
|
|
IT8942507D0
|
|
Procedure for the synthesis of conducting polymers
|
|
IT8742512D0
|
|
Conducting filter chemical prepn.
|
